COVID-19 test developer Talis Biomedical prices upsized IPO at $16 high end

Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised $221 million by offering 13.8 million shares at $16, the high end of the $14 to $16 range. Talis originally filed to sell 10 million shares, before increasing the offering toRead More